findmyKOL
Clinical trialNCT02444910CompletedPhase 2Interventional

Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects

SponsorKinDex Pharmaceuticals, Inc.Enrollment9Diabetes Mellitus, Type 2
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Philip Kern, MD

    University of Kentucky's Center for Clinical and Translational Science (CCTS)

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Kentucky'S Center for Clinical and Translational Science (ccts)

    Lexington, Kentucky, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Apr 2015
Primary completion
30 Nov 2015
Completion
30 Nov 2015
Last update posted
20 Oct 2017
Registered enrollment
9
Registry id
NCT02444910

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.